Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Phase 2
Completed
- Conditions
- Non-Hodgkin's LymphomaLymphoma, Large CellDiffuse, Mantle Cell Lymphoma, LymphomaFollicular LymphomaLarge B-Cell, Diffuse
- Interventions
- First Posted Date
- 2010-05-07
- Last Posted Date
- 2013-07-04
- Lead Sponsor
- SymBio Pharmaceuticals
- Target Recruit Count
- 63
- Registration Number
- NCT01118845
A Phase I Clinical Trial of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-cell Non-Hodgkin's Lymphoma
Phase 1
Completed
- Conditions
- Diffuse Large B-Cell LymphomaFollicular LymphomaNon-Hodgkin's LymphomaMantle Cell Lymphoma
- First Posted Date
- 2008-11-20
- Last Posted Date
- 2021-07-02
- Lead Sponsor
- SymBio Pharmaceuticals
- Target Recruit Count
- 9
- Registration Number
- NCT00794638
Clinical Study on SyB L-0501 in Patients With Indolent B-cell Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma
Phase 2
Completed
- Conditions
- Non-Hodgkin's LymphomaMantle Cell Lymphoma
- First Posted Date
- 2008-02-11
- Last Posted Date
- 2010-07-22
- Lead Sponsor
- SymBio Pharmaceuticals
- Target Recruit Count
- 56
- Registration Number
- NCT00612183
A Phase I Study of Bendamustine Hydrochloride in Patients With Indolent B-cell Non-Hodgkin's Lymphoma
Phase 1
Completed
- Conditions
- Non-Hodgkin's Lymphoma
- First Posted Date
- 2006-10-17
- Last Posted Date
- 2020-10-22
- Lead Sponsor
- SymBio Pharmaceuticals
- Target Recruit Count
- 9
- Registration Number
- NCT00389051
© Copyright 2025. All Rights Reserved by MedPath